| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918068 | Radiotherapy and Oncology | 2015 | 7 Pages |
Abstract
Although a substantial proportion of central SABR patients received ⩾60 Gy to OARs, the 3-year survival was no different from peripheral SABR.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hilâl Tekatli, Suresh Senan, Max Dahele, Ben J. Slotman, Wilko F.A.R. Verbakel,